NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
07/26/2025
Back to search
Official data from USPTO
TAIHO ONCOLOGY
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
32
Latest update
08/19/2025
Trademark type
Combined
Nice classes
5, 42, 44
Filing date
03/28/2014
Registration date
03/31/2015
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/26/2025
Last transaction
08/19/2025
Responsible office
United States Patent and Trademark Office
Status code
800
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
3
Owner type
03
Owner location
Tokyo, JP
Examiner
DELANEY, ZHALEH
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of a white oval with a brown border, containing a brown "T"-shaped design below a yellow rounded rectangular shape and a smaller red rectangular shape within the oval, all above the wording "TAIHO" in brown stylized font and "ONCOLOGY" on a second line in black stylized font.
Holders and representatives
Holders
Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical Co., Ltd.
Representatives
Karen Lim FROSS ZELNICK LEHRMAN & ZISSU, P.C.
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparationsanti-cancer agentsanti-tumor agentsanti-ulcerogenic agentsagents for treatment of immunological diseasesagents for the treatment of urinary diseasesagents for painantiemetic agentsdiagnostic agentspreparations and substances for medical purposespreparations for detecting genetic predispositions for medical purposes
Class 42
Scientific research for medical purposes in the field of cancertumorsulcerationimmunological diseasesurinary diseasesnauseavomiting and pain ; testinginspectionresearch or evaluation of pharmaceuticals; advisoryconsultancy or information services relating to testinginspectionresearch or evaluation of pharmaceuticals and medicines; providing medical and scientific research information about the results of clinical trials for pharmaceutical products ; design and development of computer hardware and software for use in the field of medicine; research and development of medical technology
Class 44
Medical diagnostic testing in the fields of cancertumorsulcerationimmunological diseasesurinary diseasesnauseavomiting and pain ; providing medical information relating to the treatment or prevention of cancertumorsulcerationimmunological diseasesurinary diseasesnauseavomiting and pain ; medical consultation services relating to the treatment and diagnosis of cancertumorsulcerationimmunological diseasesurinary diseasesnauseavomiting and pain ; medical counseling services relating to the treatment of cancertumorsulcerationimmunological diseasesurinary diseasesnauseavomiting and pain ; genetic testing for medical purposesfor the diagnosis and prognosis of the expected progression of cancertumorsulcerationimmunological diseasesurinary diseasesnauseavomiting and pain ; providing medical information relating to efficacyside effectsinteractions of pharmaceuticals and medications ; providing medical information
Publications
History of USPTO decisions and trademark events.
32 publications found
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
07/26/2025
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
07/26/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
07/26/2025
E89R
TEAS SECTION 8 & 9 RECEIVED
03/05/2025
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
03/31/2024
NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
04/07/2022
8.OK
REGISTERED - SEC. 8 (6-YR) ACCEPTED
04/07/2022
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
03/29/2022
ES8R
TEAS SECTION 8 RECEIVED
09/10/2021
CORV
REVIEW OF CORRESPONDENCE COMPLETE - ADDRESS UPDATED
04/05/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/31/2017
R.PR
REGISTERED-PRINCIPAL REGISTER
03/31/2015
PUBO
PUBLISHED FOR OPPOSITION
01/13/2015
NPUB
NOTICE OF PUBLICATION
12/24/2014
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
12/05/2014
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/01/2014
CNEA
EXAMINERS AMENDMENT MAILED
11/25/2014
XAEC
EXAMINER'S AMENDMENT ENTERED
11/24/2014
CNEA
EXAMINERS AMENDMENT -WRITTEN
11/24/2014
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/20/2014
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/20/2014
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/19/2014
CPRA
PRIORITY ACTION MAILED
07/02/2014
CPRA
PRIORITY ACTION WRITTEN
07/02/2014
DOCK
ASSIGNED TO EXAMINER
06/30/2014
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
04/25/2014
ALIE
ASSIGNED TO LIE
04/25/2014
MDSC
NOTICE OF DESIGN SEARCH CODE MAILED
04/12/2014
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/11/2014
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
04/04/2014
NWAP
NEW APPLICATION ENTERED
04/01/2014
Continuous trademark protection
Get notified about every new filing that threatens TAIHO ONCOLOGY or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.